Industry News

U. S. Food and Drug Administration granted accelerated approval to nivolumab (Opdivo Injection, Bristol-Myers Squibb Company) in combination with ipilimumab for the treatment of patients with BRAF V600 wild-type, unresectable or metastatic melanoma.

UbiVac, a privately held clinical stage immuno-oncology company, collaborate with Janssen Biotech, Inc. (Janssen), one of the Janssen Pharmaceutical Companies of Johnson & Johnson. The Johnson & Johnson Innovation Center in California facilitated the research agreement on behalf of the Janssen Disease Interception Accelerator.

Novartis's pivotal Phase III FUTURE 1 study for secukinumab in psoriatic arthritis (PsA) were published online in the New England Journal of Medicine (NEJM). Secukinumab is the first interleukin-17A (IL-17A) inhibitor to demonstrate efficacy in a Phase III study in patients with active PsA, a painful, debilitating condition causing inflammation of joints and skin. PsA is part of a family of long-term diseases impacting joints, known as spondylorarthritis.

Pfizer Inc., in partnership with five leading breast cancer advocacy organizations, today announced the next chapter of the Breast Cancer: A Story Half Told initiative, launched in 2014 to identify public misperceptions and gaps in knowledge surrounding metastatic breast cancer (MBC), the most advanced form of breast cancer. Research conducted as part of this initiative revealed that the majority of Americans (60%) reported they know little to nothing about MBC.1The new chapter aims to address this lack of understanding through the perspectives of women living with MBC, as chronicled by prominent photographers.

- Company increases its investments in India across R&D, manufacturing, people and community programs
- Abbott invests in New Mumbai corporate office in the Bandra Kurla complex

• Interim analysis of INPULSIS®-ON study shows: Beneficial effect of OFEV®* on slowing disease progression was maintained and the change from baseline in FVC was consistent over 2 years
  
• Long-term treatment with OFEV®* had a manageable safety and tolerability profile (mean exposure of 2.4 years, maximum exposure of more than 3 years)
  
• Commonly used concomitant medications, such as anti-acids or systemic steroids, do not influence the beneficial effect of OFEV®* on slowing disease progression
  

(NewsVoir); Necessity is the mother of all invention. Pharmaceuticals industry just got innovative in reaching out to doctors with the latest app for Apple Watch under the Ethical Marketing norms. Developed by Indegene, the leading provider of healthcare solutions to the global pharmaceuticals industry, medical insurers and hospitals in the US, has developed the latest app for the Apple Watch for the healthcare industry to engage with doctors. This app augurs well for the Pharma industry already reeling under pressures of compliance norms for ethical marketing to doctors.

Perrigo Company plc, received US Food and Drug Administration (FDA) approval for the generic version of Valeant Pharmaceutical International Inc's BenzaClin topical gel.

[adsense:336x280:8701650588]

B. Braun Medical Inc. (B.Braun), a leader in infusion therapy and pain management, has received 510(k) clearance for its second-generation, large-volume Infusomat Space Pump.